Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Meiji Yasuda Asset Management Co Ltd.

Meiji Yasuda Asset Management Co Ltd. lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.5% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,335 shares of the biopharmaceutical company’s stock after selling 35 shares during the period. Meiji Yasuda Asset Management Co Ltd.’s holdings in Regeneron Pharmaceuticals were worth $1,663,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Willner & Heller LLC raised its position in Regeneron Pharmaceuticals by 3.9% in the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock valued at $284,000 after purchasing an additional 15 shares in the last quarter. OLD Second National Bank of Aurora raised its holdings in Regeneron Pharmaceuticals by 0.5% in the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock valued at $2,025,000 after acquiring an additional 15 shares in the last quarter. Rakuten Securities Inc. lifted its stake in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 15 shares during the last quarter. TD Private Client Wealth LLC grew its holdings in Regeneron Pharmaceuticals by 9.6% during the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 15 shares in the last quarter. Finally, Manchester Capital Management LLC grew its holdings in Regeneron Pharmaceuticals by 12.6% during the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 18 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $640.14 on Thursday. The business has a 50 day simple moving average of $685.91 and a 200-day simple moving average of $805.04. Regeneron Pharmaceuticals, Inc. has a 12 month low of $629.02 and a 12 month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a market capitalization of $69.98 billion, a PE ratio of 16.72, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the business earned $11.86 EPS. The business’s revenue was up 10.3% on a year-over-year basis. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.55%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on REGN shares. Bernstein Bank decreased their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Robert W. Baird cut their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Finally, Wells Fargo & Company cut their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.